argenx SE (ARGX) AI Stock Analysis

argenx SE is a biotechnology company dedicated to advancing therapies for autoimmune diseases across global markets, including the United States, Japan, and several European nations. Established in 2008 and headquartered in Breda, the Netherlands, the company focuses on developing treatments for significant unmet medical needs. Its flagship product candidate, efgartigimod, is undergoing Phase III clinical trials for conditions such as myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. argenx is also advancing immunology candidates including cusatuzumab, ARGX-119, ARGX-117, ARGX-118, and ARGX-120, while maintaining partnerships with AbbVie S.à r.l., Zai Lab Limited, and LEO Pharma A/S.

argenx expanded annual revenue from $1.08B in FY2021 to $4.15B in FY2025, reflecting an 89.6% increase in FY2025 following 78.6% growth in FY2024. The business transitioned to profitability in FY2024 with net income of $833.0M, which rose to $1.29B in FY2025 alongside an operating margin of 25.4% and diluted EPS of $19.52. Research and development expenses were $1.36B in FY2025. Over the trailing twelve months, revenue reached $5.32B with an operating margin of 32.0% and a net profit margin of 32.3%. In the latest quarter ended June 30, 2026, revenue increased 59.3% year-over-year and quarterly earnings grew 95.2%.

As of June 30, 2026, argenx held $5.18B in cash and short-term investments against total debt of $47.0M, resulting in net cash of $5.14B. Total assets stood at $10.03B and shareholders' equity reached $8.42B, supporting a current ratio of 5.12 and a debt-to-equity ratio of 0.01. Operating cash flow improved to $850.5M in FY2025, generating $844.3M in free cash flow after capital expenditures of $6.2M. Over five years, the company's share count increased 25.0%.

At $819.14 per share, argenx has a market capitalization of $51.51B and an enterprise value of $54.72B. The stock trades at a trailing P/E of 31.2x and a forward P/E of 25.9x, above the median of its US-listed Healthcare peers of 24.6x trailing and 17.3x forward. Its price-to-sales ratio of 9.7x also exceeds the peer median of 4.1x, while its EV-to-EBITDA stands at 30.7x compared to the peer median of 12.0x. Over the past year, the stock returned -2.2%, trailing the S&P 500 (SPY) return of 16.8%, but delivered a 5-year return of 178.9% versus 83.0% for the index.

Wall Street coverage consists of 15 Strong Buy, 7 Buy, and 3 Hold ratings, with zero Sell recommendations. The mean price target is $1152.91, representing 40.7% upside compared to the October 16, 2026 closing price of $819.14. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $6.30B and EPS of $18.68. For the following fiscal year, analysts estimate revenue of $7.77B and EPS of $35.59. argenx beat EPS expectations in each of the last 4 quarters, and its next earnings date is October 22, 2026.

This page is an AI-written research summary of argenx SE (ARGX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ARGX income statement, ARGX balance sheet, ARGX key metrics, ARGX analyst forecast, ARGX chart. See the ARGX stock overview for the latest quote and news.